|
Billerica, Massachusetts and Mountain View, California, December 1st, 2003 (PR Newswire) - Bruker Daltonics Inc., an operating company of Bruker Biosciences Corporation (NASDAQ: BRKR), and SurroMed, Inc. today announced a strategic partnership that includes SurroMed acquisition of multiple Bruker Daltonics microTOF ESI-TOF mass spectrometers for use in SurroMed’s biomarker discovery laboratory, as well as collaboration on development of advanced software and sample fractionation products.
“The new Bruker Daltonics microTOF provides the highest resolution and mass accuracy of any benchtop ESI-TOF machine available today. In conjunction with SurroMed’s proprietary MassView software, these instruments will allow us to increase substantially the number of proteins, peptides and metabolites that we are able to identify and quantify from our samples,” said Christopher Becker, Ph.D., SurroMed’s Director of Chemistry.
“We are very pleased to be collaborating with SurroMed, a pioneer and leader in biomarker discovery,” stated Frank Laukien, Ph.D., President and CEO of Bruker Daltonics. “The high performance of our microTOF is well suited for SurroMed’s protein and metabolite biomarker profiling methods using LC/MS with high mass accuracy. In addition, the instruments are robust enough to satisfy the high-throughput requirements of SurroMed’s Biomarker Discovery Laboratory. Collaborating with SurroMed on the further development of LC-ESI/TOF based biomarker discovery tools, adds an important second dimension to our strategy as a leading tools provider for clinical proteomics.”
“We are delighted to establish this strategic relationship with Bruker Daltonics,” added Gordon Ringold, Ph.D., Chairman and CEO of SurroMed. “We look forward to collaborating on Bruker Daltonics’ development of leading edge mass spectrometry and sample fractionation products, as well as on advanced bioinformatics software for mass spectrometry based biomarker discovery. Having access to the most advanced analysis tools should further our goal of being the leading biomarker drug and diagnostics discovery company.”
About Bruker BioSciences:
Bruker BioSciences, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker Daltonics Inc. and Bruker AXS Inc. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. Bruker AXS is a leading developer and provider of life science and advanced materials research tools based on X-ray technology. For more information about Bruker BioSciences Corporation, please visit www.bruker-biosciences.com.
About SurroMed, Inc.
Headquartered in Mountain View, California, SurroMed is pioneering biomarker enabled drug discovery and development. The company focuses on discovering and applying biomarkers to improve the drug discovery and development process and enable the precise diagnosis and personalized treatment of disease. SurroMed’s research process yields biological markers and information that enable accelerated, cost-efficient discovery and development of new therapeutic products, as well as development of diagnostic tests for early disease detection, disease staging, patient stratification, and guiding and monitoring therapy.
Contacts:
SurroMed, Inc.
August J. Moretti
CFO and General Counsel
(650) 230-1564
email: [email protected]
Bruker BioSciences Corporation
Michael Willett
Investor Relations Officer
Tel: (978) 663-3660, ext. 1411
email: [email protected]
Euro RSCG Life NRP
Jeannine Medeiros
Vice President
Tel: (415) 901-3709
email: [email protected]
CAUTIONARY STATEMENT OF BRUKER BIOSCIENCES
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the Company’s products, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K for the year ended December 31, 2002, our most recent quarterly reports on Form 10-Q, our current reports on Form 8-K and the joint proxy statement/prospectus filed in connection with the merger. We disclaim any intent or obligation to update these forward-looking statements.
|